SV2001000416A - Derivados de imidazopirimidina y derivados de triazolopirimidina ref. rck 00001-sv - Google Patents

Derivados de imidazopirimidina y derivados de triazolopirimidina ref. rck 00001-sv

Info

Publication number
SV2001000416A
SV2001000416A SV2001000416A SV2001000416A SV2001000416A SV 2001000416 A SV2001000416 A SV 2001000416A SV 2001000416 A SV2001000416 A SV 2001000416A SV 2001000416 A SV2001000416 A SV 2001000416A SV 2001000416 A SV2001000416 A SV 2001000416A
Authority
SV
El Salvador
Prior art keywords
derivatives
optionally replaced
rck
ref
imidazopyrimidine
Prior art date
Application number
SV2001000416A
Other languages
English (en)
Inventor
Takeshi Yura
Arnel B Concepcion
Gyoonhee Han
Makito Hiraoka
Hiroko Yoshino
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy B Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2001000416A publication Critical patent/SV2001000416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

UN COMPUESTO DE FORMULA, VER FORMULA, EN EL QUE R1 ES -X-R4, UN RESIDUO HETEROCICLICO OPCIONALMENTE SUSTITUIDO, UN RESIDUO CARBOCICLICO OPCIONALMENTE SUSTITUIDO O UN RESTO DE ANILLO CONDENSADO OPCIONALMENTE SUSTITUIDO; X ES CR5R6, O, S, SO, SO2 O NR7; Y ES CH O N; R2 ES H, UN ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO, ETC; R4 ES UN ARILO OPCIONALMENTE SUSTITUIDO, UN HETEROARILO OPCIONALMENTE SUSTITUIDO, ETC.; R5,R6 Y R7 PUEDEN SER IDENTICOS O DIFERENTES Y REPRESENTAN H, UN ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO, ETC.EL COMPUESTO TIENE UNA EXCELENTE ACTIVIDAD ANTIALERGICA Y SIMILARES.
SV2001000416A 2000-04-28 2001-04-27 Derivados de imidazopirimidina y derivados de triazolopirimidina ref. rck 00001-sv SV2001000416A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体

Publications (1)

Publication Number Publication Date
SV2001000416A true SV2001000416A (es) 2001-07-03

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000416A SV2001000416A (es) 2000-04-28 2001-04-27 Derivados de imidazopirimidina y derivados de triazolopirimidina ref. rck 00001-sv

Country Status (38)

Country Link
US (1) US6911443B2 (es)
EP (1) EP1278750B1 (es)
JP (2) JP2001302667A (es)
KR (1) KR20030009456A (es)
CN (1) CN1263756C (es)
AR (1) AR033367A1 (es)
AT (1) ATE272639T1 (es)
AU (1) AU783043B2 (es)
BG (1) BG107166A (es)
BR (1) BR0110404A (es)
CA (1) CA2407531A1 (es)
CZ (1) CZ20023551A3 (es)
DE (1) DE60104671T2 (es)
DK (1) DK1278750T3 (es)
DO (1) DOP2001000151A (es)
EE (1) EE200200606A (es)
ES (1) ES2225546T3 (es)
HK (1) HK1058362A1 (es)
HR (1) HRP20020943A2 (es)
HU (1) HUP0300846A2 (es)
IL (1) IL151919A0 (es)
MA (1) MA25746A1 (es)
MX (1) MXPA02010579A (es)
MY (1) MY141578A (es)
NO (1) NO20025154D0 (es)
NZ (2) NZ526221A (es)
PE (1) PE20011287A1 (es)
PL (1) PL358106A1 (es)
PT (1) PT1278750E (es)
RU (1) RU2306313C2 (es)
SI (1) SI1278750T1 (es)
SK (1) SK15332002A3 (es)
SV (1) SV2001000416A (es)
TR (1) TR200402300T4 (es)
TW (1) TWI222974B (es)
UA (1) UA72615C2 (es)
WO (1) WO2001083485A1 (es)
ZA (1) ZA200207676B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
US20070129383A1 (en) * 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
SI1718649T1 (sl) * 2004-01-31 2009-10-31 Actimis Pharmaceuticals Inc Derivati imidazo 1,2-c pirimidinilocetne kisline
EP1765825A1 (en) * 2004-06-25 2007-03-28 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200800215A (en) * 2005-10-13 2008-01-01 Glaxo Group Ltd Novel compounds
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
CN101611035A (zh) 2006-12-28 2009-12-23 大正制药株式会社 吡唑并嘧啶化合物
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
AR068633A1 (es) 2007-09-25 2009-11-25 Actimis Pharmaceuticals Inc Pirimidinas sustituidas con 2-s- bencilo como antagonistas de crth2
DK2205569T3 (da) 2007-09-25 2012-05-21 Actimis Pharmaceuticals Inc Alkylthiopyrimidiner som crth2-antagonister
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
TWI478922B (zh) 2008-12-08 2015-04-01 Gilead Connenticut Inc 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
CA2765534C (en) 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
NZ603446A (en) * 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
KR20140028062A (ko) 2011-05-10 2014-03-07 머크 샤프 앤드 돔 코포레이션 Syk 억제제로서의 아미노피리미딘
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013055645A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
EP2799431B1 (en) * 2011-12-28 2018-01-24 FUJIFILM Corporation Novel nicotinamide derivative or salt thereof
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
US20160168155A1 (en) 2013-07-30 2016-06-16 Gilead Connecticut, Inc. Polymorph of syk inhibitors
WO2015084992A1 (en) 2013-12-04 2015-06-11 Gilead Sciences, Inc. Methods for treating cancers
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
JP6416275B2 (ja) * 2014-03-19 2018-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロアリールｓｙｋ阻害剤
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための組み合わせ
EA033978B1 (ru) 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
WO2019076817A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
WO2019099578A1 (en) * 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Use of imidazopyrimidine for modulating human immune response
WO2019099564A1 (en) 2017-11-14 2019-05-23 Children's Medical Center Corporation Novel imidazopyrimidine compounds and uses thereof
EP3804722A4 (en) 2018-06-06 2022-04-13 National University Corporation Hokkaido University TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
PL358106A1 (en) 2004-08-09
NZ522241A (en) 2004-04-30
DOP2001000151A (es) 2002-05-15
RU2306313C2 (ru) 2007-09-20
SI1278750T1 (en) 2005-02-28
HRP20020943A2 (en) 2005-02-28
MXPA02010579A (es) 2003-05-14
TR200402300T4 (tr) 2004-12-21
EE200200606A (et) 2004-04-15
KR20030009456A (ko) 2003-01-29
MA25746A1 (fr) 2003-04-01
DE60104671T2 (de) 2005-12-29
HUP0300846A2 (hu) 2003-08-28
JP2003535067A (ja) 2003-11-25
BG107166A (bg) 2003-06-30
ZA200207676B (en) 2003-09-25
SK15332002A3 (sk) 2003-06-03
IL151919A0 (en) 2003-04-10
NO20025154L (no) 2002-10-25
TWI222974B (en) 2004-11-01
AR033367A1 (es) 2003-12-17
AU783043B2 (en) 2005-09-22
CN1439009A (zh) 2003-08-27
NZ526221A (en) 2005-01-28
UA72615C2 (en) 2005-03-15
ATE272639T1 (de) 2004-08-15
EP1278750A1 (en) 2003-01-29
HK1058362A1 (en) 2004-05-14
DK1278750T3 (da) 2004-11-22
US6911443B2 (en) 2005-06-28
PT1278750E (pt) 2004-11-30
PE20011287A1 (es) 2002-02-27
EP1278750B1 (en) 2004-08-04
MY141578A (en) 2010-05-14
CN1263756C (zh) 2006-07-12
WO2001083485A1 (en) 2001-11-08
DE60104671D1 (de) 2004-09-09
NO20025154D0 (no) 2002-10-25
JP2001302667A (ja) 2001-10-31
CA2407531A1 (en) 2001-10-25
ES2225546T3 (es) 2005-03-16
AU6220401A (en) 2001-11-12
BR0110404A (pt) 2003-02-11
CZ20023551A3 (cs) 2003-01-15
US20040054179A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
SV2001000416A (es) Derivados de imidazopirimidina y derivados de triazolopirimidina ref. rck 00001-sv
AR006390A1 (es) Derivados de lactama
NL350077I2 (nl) Cyprosulfamide
HK1079191A1 (en) Pleuromutilin derivatives as antimicrobbials
DK1193270T3 (da) Pyrrolobenzodiazepiner
SE9702773D0 (sv) Novel compounds
DE60142355D1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
DE602004011390D1 (de) Kindgerechter einwegartikel
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
BR0015334A (pt) Derivados de pirrol como inibidores de fosfodiesterase vii
HRP20080602T3 (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h-chromium-6-yl-derivatives and drugs containing said compounds
EA200300629A1 (ru) Конденсированные производные пурина как антагонисты рецепторов аденозина a
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
ATE258930T1 (de) Dihydrobenzifurane
EA200200810A1 (ru) Конденсированные соединения азола и их применение в качестве гипогликаемических агентов
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
DE60008400D1 (de) Triazolopyrimidinderivate
MEP36808A (en) Ambroxol-containing lozenge
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
CO5080754A1 (es) Caspasas y apoptosis
ATE286887T1 (de) Antibakterielle mittel
CO5180541A1 (es) Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
AR027349A1 (es) Derivados de amidas heterociclicas
CO5180536A1 (es) Inhibidores de proteasas catepsina

Legal Events

Date Code Title Description
FD Lapse